A new technology called CryoMesh can freeze human pancreatic cells for a year and still have them work perfectly when thawed.
April 29, 2026
Original Paper
Clinical grade cryopreservation unlocks transplant ready human pancreatic and stem cell derived islets for diabetes therapy
bioRxiv · 10.64898/2026.04.25.720819
The Takeaway
Treating diabetes with cell transplants is currently a race against time because living donor cells die almost immediately after being harvested. This new vitrification platform uses a specialized mesh to flash freeze the cells without forming damaging ice crystals. This allows for the creation of global banks where life-saving cells can be stored and shipped anywhere in the world. When thawed, the cells still produce insulin just as well as fresh ones, solving a massive bottleneck in transplant medicine. It brings us one step closer to making cell therapy a routine cure for millions of people with Type 1 diabetes. This is a genuine first in the field of cryobiology.
From the abstract
Pancreatic islet transplantation can restore endogenous insulin production and offers a potential cure for diabetes, but its clinical impact has been limited by the inability to preserve large numbers of functional islets for timely use. Cryopreservation could provide an on demand supply, yet conventional methods cause ice formation, cell injury, and loss of insulin secretion. We developed CryoMesh, a vitrification platform that combines a low-toxicity cryoprotectant with a thermally conductive,